Get the Stockscreener App
1.60
6.98%
-0.12
Autolus Therapeutics Plc Adr stock is traded at $1.60, with a volume of 2.35M.
It is down -6.98% in the last 24 hours and down -14.44% over the past month.
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.
See More
Previous Close:
$1.72
Open:
$1.74
24h Volume:
2.35M
Relative Volume:
1.25
Market Cap:
$425.86M
Revenue:
$92.67M
Net Income/Loss:
$-288.81M
P/E Ratio:
-1.4744
EPS:
-1.0852
Net Cash Flow:
$-295.51M
1W Performance:
-11.60%
1M Performance:
-14.44%
6M Performance:
-0.62%
1Y Performance:
-4.76%
1-Day Range:
$1.59
$1.74
1-Week Range:
$1.59
$1.82
52-Week Range:
$1.175
$2.58
Autolus Therapeutics Plc Adr Stock (AUTL) Company Profile
Name
Autolus Therapeutics Plc Adr
Sector
Industry
Phone
44 20 3829 6230
Address
THE MEDIAWORKS, LONDON
Compare AUTL vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AUTL
Autolus Therapeutics Plc Adr
|
1.60 | 425.86M | 92.67M | -288.81M | -295.51M | -1.0852 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Autolus Therapeutics Plc Adr Stock (AUTL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-17-26 | Initiated | H.C. Wainwright | Buy |
| Nov-18-24 | Upgrade | Goldman | Neutral → Buy |
| Nov-15-24 | Upgrade | Redburn Atlantic | Neutral → Buy |
| Nov-09-23 | Initiated | Deutsche Bank | Buy |
| Mar-27-23 | Resumed | Wells Fargo | Overweight |
| Mar-17-23 | Initiated | Bryan Garnier | Buy |
| Jun-14-21 | Upgrade | Jefferies | Hold → Buy |
| Jan-29-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-28-20 | Resumed | H.C. Wainwright | Buy |
| Jul-31-20 | Initiated | JP Morgan | Overweight |
| Jul-22-20 | Initiated | SunTrust | Buy |
| Apr-22-20 | Initiated | Mizuho | Buy |
| Sep-23-19 | Initiated | Needham | Buy |
| May-17-19 | Reiterated | H.C. Wainwright | Buy |
| Oct-24-18 | Initiated | H.C. Wainwright | Buy |
View All
Autolus Therapeutics Plc Adr Stock (AUTL) Latest News
Autolus Therapeutics (NasdaqGS:AUTL) Stock Forecast & Analyst Predictions - Simply Wall Street
Autolus Therapeutics Executive Reports RSU Vesting and Share Sale in Form 4 Filing - Kalkine Media
Autolus Therapeutics (AUTL) insider reports 20,000 RSUs - Stock Titan
Autolus (NASDAQ: AUTL) holder plans ADS sale tied to tax on vested stock - Stock Titan
Autolus Therapeutics (NASDAQ:AUTL) Sets New 1-Year HighStill a Buy? - MarketBeat
Alphabet Inc. Takes Position in Autolus Therapeutics PLC Sponsored ADR $AUTL - MarketBeat
Autolus Therapeutics (NASDAQ:AUTL) Trading 6.3% HigherStill a Buy? - MarketBeat
Syncona Portfolio Ltd Buys Shares of 16,640,720 Autolus Therapeutics PLC Sponsored ADR $AUTL - MarketBeat
symbol__ Stock Quote Price and Forecast - CNN
Autolus Therapeutics (AUTL): Armistice Capital discloses 15M-share, 5.64% ADS stake - Stock Titan
Autolus Therapeutics plc (AUTL) Stock Price, News, Quote & History - Yahoo Finance
Autolus Therapeutics (NASDAQ:AUTL) Trading Down 7%Here's Why - MarketBeat
Autolus Therapeutics (NASDAQ:AUTL) Trading 13.3% Higher Following Strong Earnings - MarketBeat
Renaissance Technologies LLC Has $3.17 Million Position in Autolus Therapeutics PLC Sponsored ADR $AUTL - marketbeat.com
Autolus Secures New $250 Million Financing and Warrants - The Globe and Mail
Autolus Therapeutics (NASDAQ:AUTL) Shares Gap UpStill a Buy? - MarketBeat
Autolus Therapeutics Reports Preliminary Second Quarter 2026 Net Product Revenue and Announces Credit Facility of up to $250 Million with Perceptive Advisors - The Manila Times
AUTL Q1 2026 Earnings: EPS Misses Consensus by 2.94% as CAR-T Commercial Buildout Continues - dars.gov.et
AUTL Q1 2026 Earnings: EPS Misses Consensus by 2.94% as CAR-T Commercial Buildout ContinuesRevenue Breakdown Analysis - dars.gov.et
AUTL Q1 2026 Earnings: EPS Misses Consensus by 2.94% as CAR-T Commercial Buildout ContinuesShare Dilution Risk - www.dars.gov.et
AUTL Q1 2026 Earnings: EPS Misses Consensus by 2.94% as CAR-T Commercial Buildout ContinuesEPS Consistency Score - dars.gov.et
Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Autolus Therapeutics (NASDAQ:AUTL) Trading Down 0.7%Time to Sell? - MarketBeat
Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Autolus awards stock grants to 13 new employees - Stock Titan
AUTLAutolus Therapeutics plc ADR Options - Finviz
Autolus Therapeutics Plc Sponsored ADR Actuals & Estimates (NASDAQ:AUTL) - TradingView
Enterprise value to revenue forward of Autolus Therapeutics Plc Sponsored ADR – TRADEGATE:6A3A - TradingView
Price to book forward of Autolus Therapeutics Plc Sponsored ADR – TRADEGATE:6A3A - TradingView
Price to sales forward of Autolus Therapeutics Plc Sponsored ADR – TRADEGATE:6A3A - TradingView
Price to earnings forward of Autolus Therapeutics Plc Sponsored ADR – TRADEGATE:6A3A - TradingView
Enterprise value to EBITDA forward of Autolus Therapeutics Plc Sponsored ADR – TRADEGATE:6A3A - TradingView
Autolus Therapeutics (AUTL) could find a support soon, here's why you should buy the stock now - MSN
Autolus Therapeutics (AUTL) could find a support soon, here's why you should buy the stock now - MSN
Autolus Therapeutics (AUTL) could find a support soon, here's why you should buy the stock now - MSN
Autolus Therapeutics Receives Prix Galien UK Award - GlobeNewswire Inc.
Autolus Therapeutics (AUTL) Could Find a Support Soon, Here's Why You Should Buy the Stock Now - Yahoo Finance
Autolus Therapeutics releases annual report and schedules shareholder meeting - Investing.com
Autolus Therapeutics PLC Sponsored ADR (AUTL) Just Flashed Golden Cross Signal: Do You Buy? - sharewise.com
Autolus Therapeutics PLC Sponsored ADR (AUTL) Just Flashed Golden Cross Signal: Do You Buy? - Yahoo Finance
Autolus Therapeutics PLC Sponsored ADR (AUTL) Just Flashed Golden Cross Signal: Do You Buy? - Zacks Investment Research
Autolus Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewswire Inc.
AUTL - Finviz
Apellis Pharmaceuticals (APLS) moves 135.4% higher: Will this strength last? - MSN
Apellis Pharmaceuticals (APLS) moves 135.4% higher: Will this strength last? - MSN
Autolus Therapeutics Q1 Earnings Call Highlights - Yahoo Finance
Autolus Therapeutics (NASDAQ: AUTL) to cut 13% of staff, save $15M - Stock Titan
Autolus Therapeutics Eyes CAR-T Edge With AUCATZYL Safety, Expands Centers, Sees Margin Turnaround - Yahoo Finance
Autolus Therapeutics (NASDAQ: AUTL) registers $150M shelf for shares, ADSs, debt - Stock Titan
Autolus Therapeutics Highlights obe-cel Momentum in ALL With New Real-World ROKA and Pediatric Data - Yahoo Finance
Autolus Therapeutics Plc Adr Stock (AUTL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Autolus Therapeutics Plc Adr Stock (AUTL) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Piccina Cintia | U.S. CCO & Country Gen Manager |
Sep 02 '26 |
Sale |
2.34 |
6,713 |
15,682 |
13,287 |
| Piccina Cintia | Officer |
Sep 02 '26 |
Proposed Sale |
2.34 |
6,713 |
15,679 |
0 |
4.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):